HQL Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 geg. 2024 @ 17:28):

Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe...

Stats
Šios dienos apimtis	8 899.00
Vidutinė apimtis	99 631.00
Rinkos kapitalizacija	359.25M
Kita pelno data	( $0 ) 2024-06-03
Last Dividend	$0.300 ( 2023-11-21 )
Next Dividend	$0 ( N/A )
P/E	16.63
ATR14	$0.00600 (0.05%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-26	Saba Capital Management, L.p.	Buy	120 304	Common Stock
2024-04-25	Saba Capital Management, L.p.	Buy	97 574	Common Stock
2024-04-24	Saba Capital Management, L.p.	Buy	20 529	Common Stock
2024-04-23	Saba Capital Management, L.p.	Buy	48 203	Common Stock
2024-04-22	Saba Capital Management, L.p.	Buy	2 022	Common Stock

INSIDER POWER
100.00
Last 57 transactions
Buy: 537 850 \| Sell: 55 759

Tūris Koreliacija

Ilgas: -0.09 (neutral)

Trumpas: -0.19 (neutral)

Signal:(49.225) Neutral

Tekla Life Sciences Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
FPI	0.888
TSN	0.883
ASH	0.878
DHX	0.878
AMRC	0.874
DVN	0.873
CWT	0.871
PDS	0.868
CVX	0.867
EBR-B	0.864

10 Labiausiai neigiamai susiję koreliacijos
VCRA	-0.862
AMAM	-0.861
COR	-0.86
SCX	-0.856
IOT	-0.853
NGL	-0.845
FPAC-UN	-0.845
MOG-B	-0.842
TNK	-0.835
TK	-0.831

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Tekla Life Sciences Koreliacija - Valiuta/Žaliavos

-0.07
( neutral )

0.06
( neutral )

0.00
( neutral )

0.29
( neutral )

0.07
( neutral )

Tekla Life Sciences Finansinės ataskaitos

Annual	2023
Pajamos:	$23.52M
Bruto pelnas:	$18.28M (77.71 %)
EPS:	$0.830

FY	2023
Pajamos:	$23.52M
Bruto pelnas:	$18.28M (77.71 %)
EPS:	$0.830

FY	2022
Pajamos:	$-103.25M
Bruto pelnas:	$-108.80M (105.37 %)
EPS:	$-4.07

FY	2021
Pajamos:	$65.69M
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$2.78

Financial Reports:

No articles found.

Tekla Life Sciences Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0.310 (N/A)	$0.310 (N/A)	$0.330 (N/A)	$0.320 (N/A)	$0.320 (N/A)	$0.300 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Tekla Life Sciences Dividend Information - Dividend King

Dividend Sustainability Score: 1.232 - low (50.00%) | Divividend Growth Potential Score: 1.007 - No dividend expected

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$1.640	1996-11-14
Last Dividend	$0.300	2023-11-21
Next Dividend	$0	N/A
Payout Date	2024-01-10
Next Payout Date	N/A
# dividends	99	--
Total Paid Out	$43.17	--
Avg. Dividend % Per Year	5.54%	--
Score	5.04	--
Div. Sustainability Score	1.232
Div.Growth Potential Score	1.007
Div. Directional Score	1.119	--

Next Divdend (Est)
(2024-05-06)

$0.326 Estimate 38.53 %

Dividend Stability

0.77 Good

Dividend Score

5.04

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
1996	$1.640	10.80%
1997	$0.740	5.38%
1998	$0.360	2.76%
1999	$1.110	9.06%
2000	$4.16	20.50%
2001	$3.14	14.90%
2002	$2.18	10.20%
2003	$1.240	10.10%
2004	$1.365	8.62%
2005	$2.06	13.00%
2006	$1.240	7.90%
2007	$1.170	8.74%
2008	$1.100	8.33%
2009	$0.420	4.59%
2010	$0.520	5.46%
2011	$1.010	9.29%
2012	$1.160	10.00%
2013	$1.390	9.19%
2014	$1.770	8.72%
2015	$2.80	11.20%
2016	$2.07	8.99%
2017	$1.620	9.38%
2018	$1.620	8.18%
2019	$1.400	9.03%
2020	$1.560	8.98%
2021	$1.690	8.71%
2022	$1.360	7.05%
2023	$1.270	8.87%
2024	$0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NYSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
LOMA	Dividend Knight	2023-06-30	Quarterly	2	5.23%	8.53
ZTR	Dividend King	2024-02-09	Monthly	37	8.35%	8.50
ORC	Dividend Royal	2023-11-29	Monthly	12	9.23%	8.50
KIO	Dividend Royal	2023-12-14	Monthly	12	7.05%	8.50
NCZ	Dividend Royal	2024-02-09	Monthly	22	7.79%	8.50
SCM	Dividend King	2023-12-15	Monthly	13	7.08%	8.50
SJT	Dividend Royal	2023-11-29	Monthly	39	12.52%	8.50
GOF	Dividend Royal	2023-11-14	Monthly	18	8.03%	8.50
SRV	Dividend Royal	2023-12-04	Monthly	18	7.53%	8.50
VGI	Dividend Royal	2024-02-09	Monthly	13	7.36%	8.50

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.568	1.500	10.00	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0556	1.200	8.15	9.78	[0 - 0.3]
returnOnEquityTTM	0.0813	1.500	-0.207	-0.311	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	0	1.000	-1.111	-1.111	[3 - 30]
operatingCashFlowPerShareTTM	0.0000000	2.00	0.0000000	0.0000000	[0 - 30]
freeCashFlowPerShareTTM	0.0000000	2.00	0.0000000	0.0000000	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.867	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	0.568	1.000	0.649	0.649	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0.0978	0.800	-2.68	-2.14	[0.5 - 2]
Total Score				1.232

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	15.67	1.000	8.52	0	[1 - 100]
returnOnEquityTTM	0.0813	2.50	-0.133	-0.311	[0.1 - 1.5]
freeCashFlowPerShareTTM	0.0000000	2.00	0.0000000	0.0000000	[0 - 30]
dividendYielPercentageTTM	10.17	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	0.0000000	2.00	0.0000000	0.0000000	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-0.0619	1.500	-3.75	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0000000	1.000	-2.50	0	[0.1 - 0.5]
Total Score				1.007

Tekla Life Sciences

Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. It was formerly known as H&Q Life Sciences Investors fund. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.